C4 Therapeutics, Inc.
CCCCC4 Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted protein degradation therapies for serious diseases, including cancer and rare disorders. Utilizing its proprietary Controlled Covalent Catalysis (C4) platform, the company designs small molecules that selectively bind to and induce the degradation of disease-causing proteins, aiming to create innovative treatments with improved efficacy and safety profiles.
Company News
C4 Therapeutics (CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, announced its management will participate in three major healthcare conferences in May and June 2026, including TD Cowen's Oncology Innovation Summit, Jefferies Global Healthcare Conference, and Goldman Sachs Global Healthcare Conference. T...
C4 Therapeutics (CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026 in New York. The company is progressing targeted oncology programs including cemsidomide Phase 2 MOME...
C4 Therapeutics announced strategic milestones through 2028 for advancing cemsidomide, an investigational IKZF1/3 degrader for multiple myeloma. The company plans to initiate Phase 2 MOMENTUM trial in Q1 2026 and Phase 1b combination trial with elranatamab in Q2 2026, with a recommended Phase 2 dose of 100 µg. Phase 1 data showed 53% overall res...
C4 Therapeutics, a clinical-stage biopharmaceutical company focused on protein degradation science, will participate in the 8th Annual Evercore Healthcare Conference on December 3rd, 2025, presenting a fireside chat with live webcast.
C4 Therapeutics saw a significant stock price increase of over 34% after Stephens analyst Sudan Loganathan upgraded the stock to overweight, citing promising pipeline progress and potential in multiple myeloma drug market.
